Startup revolutionizes diagnostics in dermatology

Dermagnostix closes seven-figure seed round

17-Dec-2021 - Dermagnostix revolutionizes diagnostics in dermatology with its fully auto-mated "lab-in-a-box" system, which allows the technically valid performance of complex molecular assays. "Modern molecular diagnostics is a prerequisite for implementing precision medicine in dermatology. It not only ...

Bosch develops rapid test for COVID-19

Test results enable differential diagnosis in under 2.5 hours

31-Mar-2020 - The coronavirus SARS-CoV-2 is posing major challenges for healthcare systems and medical institutions worldwide. An ability to rapidly diagnose the virus is of invaluable help in curbing its exponential spread in many countries. Bosch’s new, fully automated rapid test for COVID-19 can help ...

Molzym is Part of Gradian Diagnostics

11-Feb-2020 - Gradian Diagnostics announced that Molzym GmbH & Co. KG is joining Gradian Diagnostics. Molzym will become the first acquisition, bringing a wide set of products and services due to their wealth of experience and expertise in molecular microbial analysis, and their focus on deep research and ...

Hummingbird Diagnostics and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

16-Nov-2017 - Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the validation of ...

A signal boost for molecular microscopy

Cavity-enhanced Raman-scattering reveals information on structure and properties of carbon nanotubes

14-Jul-2016 - Carbon nanotubes can be produced with a variety of shapes and properties and are therefore of much interest for widespread applications in fields as diverse as electronics, photonics, nanomechanics, and quantum optics. Hence it is important to have a tool at hand that allows to determine these ...

Merck and Biocartis to Collaborate

08-Jan-2016 - Merck announced that it has signed a collaboration agreement with Biocartis for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis’ innovative, fully automated molecular ...

GNA Biosolutions completes € 6 million financing round

Prepares for market entry with fast diagnostic instruments for hospital bugs

03-Jul-2015 - GNA Biosolutions GmbH (GNA), a manufacturer of ultrafast pathogen diagnostic instruments, will receive fresh capital of € 6 million in a series B financing round. Founded in 2010, GNA welcomes new investors Robert Bosch Venture Capital (RBVC), SHS Gesellschaft für Beteiligungsmanagement GmbH, ...

Curetis AG attracts Forbion and Roche as new investors

Series A financing round expanded to €34.1 million

31-Oct-2011 - Curetis AG announced the expansion of its Series A financing round by € 9.6 million. The additional funds increase the round to a total of € 34.1 million and the total capital raised to date to € 36.6 million. The financing was led by Forbion Capital Partners together with Roche Venture Fund. ...

Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer

02-Sep-2011 - Abbott announced the availability of a new molecular test in the European Union and New Zealand designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer (NSCLC). These rearrangements in a gene known as ALK (anaplastic lymphoma kinase) ...

ATLAS Biolabs fulfills the DIN EN ISO 13485:2003 + AC: 2009 standard for designing and manufacturing medical devices

13-May-2011 - By gaining certification according to the internationally recognized quality standard DIN EN ISO 13485 + AC:2009, ATLAS Biolabs GmbH has reached another milestone in its advances in the field of molecular diagnostics. DIN EN ISO 13485 + AC:2009 provides the criteria for quality management in the ...